Director Global Medical Affairs

Q32 Bio has completed its merger with Homology Medicines and a concurrent $42 million private placement. The combined company, operating as Q32 Bio, will trade on Nasdaq under ticker symbol "QTTB" from 26 March 2024. Investors in the private placement include OrbiMed, Atlas Venture, Abingworth, Bristol Myers Squibb, Acorn Bioventures, Osage University Partners, CU Healthcare Innovation Fund, Sanofi Ventures, Agent Capital and others. Following the transactions, Q32 Bio holds approximately $130 million in cash, cash equivalents and investments, expected to fund operations through mid-2026. The company will focus on advancing bempikibart in Phase 2 trials for atopic dermatitis and alopecia areata, with results expected in the second half of 2024, and commencing ADX-097 Phase 2 trials for complement disorders, with results anticipated in the second half of 2025.

Cytokinetics sues Bristol Myers to void a new patent. Cytokinetics has asked a court to strike down a newly granted Bristol Myers Squibb patent, moving a hard-fought commercial fight between two cardiac drug developers into the courtroom. Cytokinetics Inc (NASDAQ: CYTK) filed suit against Bristol-Myers Squibb Co (NYSE: BMY) on Wednesday seeking to invalidate a recently granted Bristol patent, turning a commercial rivalry between the two heart-drug developers into litigation; Cytokinetics traded at $74.18, up 0.99%, while Bristol was at $64.29, down 0.56%, as of 18:56 GMT on Aug. 14, 2026. Cytokinetics Inc (NASDAQ: CYTK) has taken its fight with Bristol-Myers Squibb Co (NYSE: BMY) out of the sales channel and into a courtroom. The company filed a lawsuit on Wednesday seeking to invalidate a patent recently granted to Bristol, according to Endpoints News, which described the two drugmakers as fierce market rivals now facing each other as litigants as well. The move is unusual in its direction. Patent fights in branded pharma are typically brought by the patent holder against a would-be entrant. Here the challenge runs the other way: the smaller company is asking a court to strike down protection the larger one has just secured, rather than waiting to be accused of infringing it. That is the posture a company adopts when it believes a competitor's newly issued claims could be read broadly enough to reach across the aisle. A commercial rivalry that had nowhere else to go. Cytokinetics and Bristol have spent years on opposite sides of the same therapeutic problem: treating patients whose heart muscle contracts too forcefully. Bristol got there first commercially through its acquisition of MyoKardia and the cardiac myosin inhibitor franchise that came with it. Cytokinetics has built its identity around its own next-generation candidate in the same mechanism class. Two companies chasing the same prescriber base with drugs that work the same way is a recipe for overlapping intellectual property, and eventually for someone testing the boundaries in court. For Cytokinetics, the stakes are structural. It is a company whose valuation rests heavily on a single cardiovascular program and the freedom to commercialize it without paying tolls to a competitor. A patent that shadows that launch is not a nuisance; it is a claim on future margin. Filing to invalidate it early, before any infringement allegation forces the company onto the back foot, keeps the initiative on Cytokinetics' side of the table and puts a clock on the dispute. For Bristol, the calculus is different. The company is large enough that a single patent challenge on one cardiology asset does not move the consolidated picture much. But it is also a company managing a well-documented loss-of-exclusivity cycle across older products, which makes newer, growing franchises disproportionately important to the forward story. Defending the durability of protection around a growth product matters more than the immediate dollars in dispute. Where the two stocks stood as the filing landed. Markets treated the news as a governance-and-timeline item rather than a shock. As of the last trade at 18:56 GMT on Friday, Aug. 14, 2026, Cytokinetics changed hands at $74.18, up 0.99% on the day from a prior close of $73.45, having traded between $72.12 and $74.27. Bristol was at $64.29, down 0.56% from a prior close of $64.65, in a $63.35 to $64.33 range. The backdrop was mildly negative. The S&P 500, via SPY, was at $776.29, off 0.20%; the Nasdaq 100 proxy QQQ was at $729.84, down 0.30%; and the Dow tracker DIA sat at $537.48, lower by 0.08%. Against that, Cytokinetics' gain reads as modest relative outperformance and Bristol's decline as roughly in line with a soft tape. Neither move suggests investors have repriced the outcome of the case in either direction - which is what you would expect at the filing stage, when there is a complaint on a docket and nothing else. What actually gets decided, and how slowly. Patent invalidation is a long game. A declaratory action of this kind typically has to clear procedural questions first - whether the plaintiff has standing to sue over a patent it has not been accused of infringing, and whether the dispute is ripe. Only then does a court reach the substance: whether the claims as granted are novel and non-obvious in light of what was already known. Appeals follow. Nothing about the trajectory of either company's revenue changes in the next quarter because of a complaint filed on a Wednesday. Only then does a court reach the substance: whether the claims as granted are novel and non-obvious in light of what was already known. What can change sooner is behavior. Litigation of this type often runs in parallel with, or ends in, a negotiated outcome - a license, a royalty, a covenant not to sue, a narrowing of claims. Companies file to create leverage as often as to win a judgment. The existence of the suit tells you the parties could not reach terms privately; the eventual resolution will tell you which side had the stronger read on the claims. Signals worth tracking from here. * Bristol's response. A counterclaim for infringement would sharpen the dispute considerably and signal confidence in the patent's breadth. A motion to dismiss on standing would suggest a preference to keep the claims untested. * Parallel administrative challenges. Invalidity arguments are frequently pressed at the patent office as well as in district court. A second front would show Cytokinetics is committed to the fight rather than posturing. * Language in filings and calls. Risk-factor updates and any discussion of the litigation in quarterly disclosures will indicate how material each company considers the exposure. * Commercial share. The court case is a sideshow to the real contest - which drug prescribers reach for. Prescription trends will drive both stocks far more over the next year than any docket entry. For investors, the practical framing is that this is a risk-boundary story, not an earnings story. Cytokinetics is trying to remove an obstacle before it becomes expensive; Bristol is defending an asset it paid to acquire. Both objectives are rational, which is precisely why the matter ended up in front of a judge. Key facts. * Cytokinetics (NASDAQ: CYTK): $74.18, +0.99%, as of 18:56 GMT Aug. 14, 2026 * Bristol-Myers Squibb (NYSE: BMY): $64.29, -0.56%, as of 18:56 GMT Aug. 14, 2026 * Action filed: Lawsuit brought Wednesday seeking to invalidate a recently granted Bristol patent * Market backdrop: S&P 500 proxy SPY $776.29 (-0.20%); Nasdaq 100 proxy QQQ $729.84 (-0.30%) Frequently asked questions. What did Cytokinetics actually file? Cytokinetics filed a lawsuit against Bristol Myers Squibb on Wednesday asking a court to invalidate a patent that had recently been granted to Bristol. Rather than defending itself against an infringement claim, Cytokinetics is affirmatively challenging the validity of the competitor's newly issued patent claims before any dispute over infringement is brought against it. Why would a company sue to cancel a rival's patent? Because a broadly worded patent held by a competitor can create royalty obligations, injunction risk or licensing leverage over a product a company plans to sell. Challenging validity early removes that overhang on the challenger's own timetable instead of leaving it to the patent holder to choose when and where to press an infringement claim. How did the two stocks react? Modestly and in opposite directions. As of the last trade at 18:56 GMT on Aug. 14, 2026, Cytokinetics was at $74.18, up 0.99% from a $73.45 prior close, while Bristol-Myers Squibb was at $64.29, down 0.56% from $64.65. Broad indices were slightly lower the same session, so neither move implies a decisive market verdict. How long could the litigation take? Patent invalidity disputes generally run for years. A court must first address procedural questions such as standing and ripeness, then reach the merits of whether the claims are novel and non-obvious, with appeals possible afterward. Many such cases settle before final judgment through licensing terms or a narrowing of the disputed claims. Does this change either company's financial outlook now? No. A complaint being docketed does not alter reported revenue, costs or guidance in the near term. The financial consequence, if any, arrives later through a judgment, a license, a royalty arrangement or legal expense. In the meantime prescription trends and commercial execution matter far more to both stocks. What should investors watch next in the case? Bristol's response is the key signal: a counterclaim alleging infringement would escalate matters, while a motion to dismiss on standing grounds would suggest an effort to avoid testing the patent. Also worth tracking are any parallel challenges at the patent office and how each company characterizes the exposure in its disclosures.

Bristol Myers Squibb to build new plant in Houston. Rendering of Bristol Myers Squibb's planned $2.3 billion state-of-the-art manufacturing campus in Houston, Texas. [Image courtesy of BMS] Bristol Myers Squibb (NYSE:BMY) announced the selection of Houston, Texas, as the site for a new 600,000 square-foot multi-modal manufacturing campus, representing an approximately $2.3 billion investment. The campus, at Generation Park in Houston, will create nearly 500 skilled jobs, the company said. The campus' multi-modal capabilities will allow BMS to manufacture multiple types of medicines - such as small molecules, biologics and antibody-drug conjugates - across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch, the company said. "This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation," Christopher Boerner, Ph.D., Board Chair and CEO, said in a press release. "As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs." Boerner announced the company's $40 billion commitment to manufacturing in the U.S. in an op-ed in STAT last year as Eli Lilly, Johnson & Johnson and others made similar commitments in response to President Donald Trump's threats of pharma tariffs, which he said would be waived for companies with onshore manufacturing capabilities. "Texas is a global hub for life sciences, where today's innovations shape the future of healthcare," Texas Gov. Greg Abbott said in a press release. "This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities." BMS also expects to create approximately 2,000 construction and other indirect jobs between 2027-2030 as the facility is built and brought online, supporting the local economy throughout the construction period, the company said. The company currently works with a Contract Manufacturer in Texas for both commercial and clinical trial manufacturing and, in 2025, had 250 clinical trial sites throughout the state to advance clinical research across its portfolio. Eli Lilly has a $6.5 billion manufacturing facility in the same Generation Park development. The facility, announced in September 2025, focuses on manufacturing small-molecule medicines, including the company's experimental oral GLP-1. Construction is set to finish in 2030.